Business
MAIA Biotechnology Announces Director Participation in Recent Private Placement
CHICAGO, May 14, 2025--MAIA Biotechnology Announces Director Participation in Recent Private Placement
About this update from Maia Biotechnology, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/cd60c3df0db0e1ff482bdb8702120ffc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/B78cuRWngfizy3fCQLnMvg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM2NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/cd60c3df0db0e1ff482bdb8702120ffc","width":960,"height":365},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/VeLz1zOIZVojgv_Z2.dQ3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD03NjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/cd60c3df0db0e1ff482bdb8702120ffc","width":1000,"height":380}},"lazy":false},{"type":"text","content":"CHICAGO, May 14, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that two of the Company’s independent directors, Stan V. Smith, Ph.D. and Ramiro Guerrero, JD, LL.M., purchased common stock and warrants in the Company’s private placement offering which closed on May 8, 2025. Gross proceeds from the offering across all investors totaled $1.08 million.","length":537,"tagName":"p"},{"type":"text","content":"Dr. Smith purchased a total of 66,666 shares and 66,666 warrants for an aggregate purchase price of approximately $100,000. Mr. Guerrero purchased a total of 20,000 shares and 20,000 warrants for an aggregate purchase price of $30,000.","length":235,"tagName":"p"},{"type":"text","content":""Stan, Ramiro and our other independent directors have been consistent investors in the Company’s financings, which I believe signals the Board's confidence in our strategic direction and future market prospects for our novel cancer immunotherapies," said MAIA Chairman and CEO Vlad Vitoc, M.D.","length":308,"tagName":"p"},{"type":"text","content":"Dr. Smith commented, "I have participated in nearly all of MAIA’s financings since its founding, and my conviction in the Company is stronger than ever. In my opinion, the clinical and regulatory strategies are thorough, and, as a potential first-in-class cancer telomere targeting treatment, the commercial opportunity for ateganosine is substantial."","length":362,"...